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Background/Aims: Studies have investigated the use 
of different types of radiofrequency capsules for com-
parison or sequential capsule endoscopy, but none have 
compared the MiroCam device - which utilizes a novel 
data transmission technology - with other capsules. 
This study compared the feasibility of sequential cap-
sule endoscopy using the MiroCam and PillCam SB 
devices, which employ different transmission technologies. 
Methods: Patients with diseases requiring capsule en-
doscopy were enrolled. After a 12-hour fast, one rando-
mly selected capsule was swallowed. The second 
capsule was swallowed once fluoroscopy had indicated 
that the first capsule had migrated below the gastric 
outlet. Results: The total operating time in 24 pa-
tients was 702±60 min (mean±SD) for the MiroCam 
and 446±28 min for the PillCam SB (p＜0.0001). The 
rate of a complete examination to the cecum was 
83.3% for the MiroCam and 58.3% for the PillCam 
SB (p=0.031). Diagnostic yields for the MiroCam, PillCam 
SB, and sequential capsule endoscopy were 45.8%, 
41.7%, and 50.0%, respectively. The agreement rate 
between the two capsules was 87.5%, with a κ val-
ue of 0.74. Electrical interference in data transmission 
between the two capsules was not observed, but tem-
porary visual interferences were observed in seven 
patients (29.2%). Conclusions: Sequential capsule 
endoscopy with the MiroCam and PillCam SB pro-
duced slight but nonsignificant increases in the diag-
nostic yield, and the two capsules did not exhibit 
electrical interference. A larger trial is necessary for 
elucidating the usefulness of sequential capsule endo-
scopy. (Gut Liver 2010;4:192-200)
Key Words: Capsule endoscopy; Gastrointestinal he-
morrhage; Feasibility study; Diagnosis
INTRODUCTION
  M2A (renamed PillCam SB; Given Imaging, Yokneam, 
Israel) was the first developed wireless capsule endoscope 
providing noninvasive and visual diagnosis of small bowel 
disease. Capsule endoscopy (CE) provides great diagnostic 
value in various small bowel diseases compared to con-
ventional modalities.1,2 Recently, other new wireless cap-
sule endoscopes including EndoCapsule (Olympus, Tokyo, 
Japan) and MiroCam (IntroMedic, Seoul, Korea), have be-
come available for small bowel examination in clinical 
situations.3,4 Among them, MiroCam received both 
Korean market clearance and the Conformité Européenne 
(CE) mark in 2007. 
  MiroCam uses a novel technology for data trans-
mission, Human Body Communication, which is different 
from the radiofrequency telemetry of PillCam SB and 
EndoCapsule.3 Human Body Communication uses the hu-
man body as a conductive medium for data transmission 
from the capsule endoscope to electrodes attached to the 
body.4 As a result, this technology spends less electrical 
power for data transmission, confers a longer operating 
time with a small size (24×11 mm), and provides high-
er-resolution images (320×320 pixels at 3 frames per sec-
ond) compared to PillCam SB.4 Longer operating times 
may reduce the rate of incomplete examinations to the 
cecum by CE, which has been reported to be 17-25% 
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throughout the lifetime of the battery.5,6 However, no 
prospective randomized trial has been reported in dis-
eased patients to compare the operating times, complete 
examination rates to the cecum, and diagnostic yields be-
tween MiroCam and PillCam SB.
  The concept of sequential CE originated from previous 
studies on repeat examinations with CE. Repeat CE and 
second-look CE in selected patients with non-diagnostic 
results during their first CE have identified additional 
new findings in patients with recurrent or persistent ob-
scure gastrointestinal (GI) bleeding and iron deficiency 
anemia.7-9 Therefore, sequential CE with two capsules in 
all subjects could increase diagnostic yield, compared to a 
single CE.
  We tested the feasibility of sequential CE utilizing 
MiroCam and PillCam SB, and also compared two capsule 
endoscopes in a prospective randomized design. 
MATERIALS AND METHODS
1. Patients
  Patients with an indication for CE, such as obscure GI 
bleeding, chronic abdominal pain, and chronic diarrhea 
were enrolled. Patient ages ranged from 20 to 75 years. 
Patients with a history of intestinal obstruction and those 
with swallowing difficulties were excluded. The patients 
with obscure GI bleeding underwent esophagogastroduod-
enoscopy and colonoscopy prior to CE examination. 
Approval was obtained from the institutional review 
board of Severance Hospital (Seoul, Korea). Written in-
formed consent was obtained from each patient.
2. Procedures of sequential CE
  Enrolled patients fasted for 12 hours, and on the day of 
examination, swallowed 30 mL of simethicone 30 minutes 
before the first CE. The order of swallowing two capsules 
was randomized. Eight antenna or electrodes were at-
tached to the abdominal wall according to the manu-
facturer’s instructions. The first capsule endoscope was 
swallowed with water, and its location was traced under 
fluoroscopy at 30 minutes intervals. After the first capsu-
le endoscope passed through the gastric outlet, the sec-
ond capsule endoscope was ingested with water. Both the 
antennas and electrodes were detached simultaneously af-
ter sufficient battery time of MiroCam or PillCam SB. 
Data from each capsule endoscope were uploaded to re-
spective computer installed with the appropriate reading 
software.
3. Data analysis 
  Two gastroenterologists interpreted the images from 
each capsule endoscope, and were kept from knowing the 
results from the other capsule endoscope. When two gas-
troenterologists reviewing the same patient were not in 
agreement, a third gastroenterologist assisted in the inter-
pretation of the images. The readers were not completely 
blinded because the reading programs were clearly distinct. 
The personal history and information from other modal-
ities were not informed to the readers. Abnormal findings 
of CE images were labeled according to the Capsule 
Endoscopy Structured Terminology (CEST).10 We classi-
fied mucosal lesions of the small bowel into three 
categories. Significant abnormal findings were defined as 
mucosal lesions strongly associated with disease. Abnor-
mal findings were defined as any mucosal lesion. Clinical 
diagnoses were made based on clinical signs and symp-
toms of the patients and interpretation of images with 
significant abnormal findings. Diagnostic yield was calcu-
lated as the number of patients with significant abnormal 
findings divided by the number of all patients.
  Operating times of the two capsule endoscopes were 
compared with the paired t-test, and completion rates and 
diagnostic yields were compared using McNemar test. 
The kappa test was used to measure an agreement be-
tween MiroCam and PillCam SB. p-values were consid-
ered to be significant when they were less than 0.05. 
RESULTS
  Twenty four patients were enrolled between June 2007 
and January 2009 (Table 1). The mean age was 52.6± 
16.7 years. Indications of CE were obscure GI bleeding in 
22 patients (91.7%) with a lowest hemoglobin concen-
tration of mean 8.2±2.0 g/dL, chronic diarrhea in one pa-
tient, and abdominal pain in one patient. The mean inter-
val time of ingestion between MiroCam and PillCam SB 
was 3 h 7 min±3 h 58 min. The mean total operating 
times of MiroCam and PillCam SB were 11 h 44 min±1 
h, and 7 h 26 min±28 min (p＜0.0001), respectively. Com-
pletion rates to the cecum by MiroCam and PillCam SB 
was 83.3% and 58.3%, respectively (p=0.031). Diagnostic 
yields of MiroCam and PillCam SB were 45.8% and 41.7% 
(p＞0.05), respectively. The sequential CE of two capsules 
slightly increased the diagnostic yield to 50.0% compared 
to a single CE, but this difference was not statistically 
significant (Table 2). The agreement rate between MiroCam 
and PillCam SB was 87.5% with a kappa value of 0.74 
(Table 3). No complication related to CE occurred. Inter-
ference of electrical transmission between MiroCam and 
PillCam SB was not observed in any patient, and images 
were captured and transferred completely during the life-
time of the battery. However, temporary visual interferences 
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Fig. 1. Temporary visual interferences and tumbling movements of the MiroCam and PillCam SB. Oblique-forward movement (A),
oblique-reverse movement (B), and perpendicular and rotational movements (C).
Table 3. Agreement between the MiroCam and PillCam SB
PillCam SB
Negative
Significant 
abnormal
Total
MiroCam Negative 12 1 13
Significant abnormal 2 9 11
Total 14 10 24
Table 2. Diagnostic Yields for Detecting Significant Abnormal
Findings in Capsule Endoscopy
Diagnostic yield (%)
  Single CE
    MiroCam 45.8
    PillCam SB 41.7
  Sequential CE (MiroCam＋PillCam SB) 50.0
CE, capsule endoscopy.
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Fig. 2. In patient 7, the MiroCam
reveales a polypoid mass in the 
distal ileum at 11：31 (C, D), 
but the PillCam SB is not able 
to capture the lesion due to its 
shorter battery life (A, B).
disturbing front visual fields due to physical obstruction 
of the capsule were observed in seven patients (29.2%) 
(Fig. 1).
DISCUSSION
  The concept of second-look CE was first reported in 
2004.8 “Repeat CE” have revealed new findings not pre-
viously observed in prior CE in patients with obscure GI 
bleeding in two studies.7,9 The second-look CE or repeat 
CE was performed on selected patients with negative 
finding in prior CE, but the sequential CE was a proce-
dure of continuous swallowing two capsules in all patients. 
The sequential CE has been prospectively attempted in 
three studies.11-13 One of them, using two same capsules 
of PillCam SB, reported that the second capsule found 
10% more new lesions in 41 patients with obscure GI 
bleeding.13 In other trial, the combination of PillCam SB 
and EndoCapsule showed increase in the diagnostic yield 
from 33.3% or 47.1% of each single capsule endoscope 
up to 52.9% in patients with obscure GI bleeding.12 In 
another study, the combination of PillCam SB (65%) and 
EndoCapsule (72.5%) revealed 77.5% of the detection 
rate of abnormal lesions in 40 patients with obscure GI 
bleeding.11 Our study showed that the combination of 
MiroCam and PillCam SB had 50% of the detection rate 
in 22 patients with obscure GI bleeding. However, we did 
not prove the significant efficacy of sequential CE, com-
pared to single CE. Further trials for investigation of the 
efficacy of sequential CE will be needed.
  Since the development of M2A, several different types 
of capsule endoscopes have become commercially available. 
EndoCapsule was developed by Olympus Medical System, 
and utilizes charged coupled device (CCD) technology for 
the image sensor, rather than the complementary metal 
oxide semiconductor (CMOS) of PillCam SB and MiroCam.3 
EndoCapsule had a comparable diagnostic yield to PillCam 
SB for obscure GI bleeding in two randomized trials.11,12 
In addition, EndoCapsule had a significantly longer re-
cording time than PillCam SB (591 min vs 471 min, re-
spectively), and a higher frequency of identifying abnor-
mal findings than PillCam SB (47.1% vs 33.3%).11,12 
MiroCam uses a different technology for data trans-
mission from PillCam SB and EndoCapsule. Our study 
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Fig. 3. In patient 5, the PillCam 
SB reveales active bleeding from
an ulcer (A, B), but the MiroCam
showes only ulcer without active
bleeding at the distal ileum, which
is suspected to be the same site 
as in A and B (C, D).
was the first pilot study to directly compare MiroCam 
and PillCam SB, and demonstrated that MiroCam had 
longer operating time than PillCam SB, and a comparable 
diagnostic yield to PillCam SB. Our study showed the rel-
atively low diagnostic yields for obscure GI bleeding 
(45.5% in MiroCam and 40.9% in PillCam SB among 22 
patients), but the low values are close to rates of other 
studies.1,5
  EndoCapsule does not electrically interfere with PillCam 
SB, even when operating in the same patient, although 
both the capsules use the same radiofrequency communi-
cation for data transmission.11,12 MiroCam also did not in-
teract with PillCam SB in our study. Two of the same 
capsules will cause electrical interference when operating 
simultaneously in the same patient on the same day. 
Therefore, a long lag-time greater than the battery life-
time of the capsule is needed to successfully perform se-
quential CE with two same capsules.13 Sequential CE of 
two different capsules can be performed in the same day, 
after a short time interval to avoid visual interference. 
Moreover, sequential CE may increase the detection rate 
of abnormal findings in the small intestine. 
  In our study, MiroCam had a higher complete examina-
tion rate to the cecum than PillCam SB. The completion 
rate of PillCam SB was lower than those in other reports.6 
However Rastogi et al.14 reported 50% of incompletion 
rate of PillCam SB. This low rate might be caused by 
sampling bias. If an abnormal lesion is located in the dis-
tal ileum, MiroCam is more likely to detect it than 
PillCam SB. For example, in one patient, MiroCam found 
a large polypoid mass at 11 h 31 min in the distal ileum, 
whereas PillCam SB was unable to detect the lesion be-
cause its short battery lifetime expired after 7 h 45 min 
(Fig. 2). The risk factors for incomplete examination of 
CE in the small bowel are long gastric transit time, pre-
vious small bowel surgery, hospitalization, and poor bow-
el cleansing in a retrospective study using PillCam SB.15,16 
Sufficiently long operating times of capsule endoscope can 
overcome some portion of these risk factors.
  Indications of CE include obscure GI bleeding, small 
bowel Crohn’s disease, small bowel tumors, celiac disease 
and abdominal pain. In our study, obscure GI bleeding 
was a major indication (91.7%) of CE although all in-
dications of CE were included. High prevalence of ob-
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Fig. 4. Patient 14 has a history 
of pelvic radiotherapy. The Pill-
Cam SB (A, B) and MiroCam 
(C, D) reveales stricture with 
ulcer, suggesting a bleeding 
focus.
scure GI bleeding might cause this selection bias. In addi-
tion, other indications, small bowel Crohn’s disease, 
small bowel tumors, celiac disease and abdominal pain, 
have low diagnostic rate of positive findings on CE, and 
therefore a lot of subjects may be necessary for evaluation 
of efficacy of sequential CE.17-19
  It is well documented that nonsteroidal anti-inflamma-
tory drug (NSAID) can cause small bowel mucosal injury, 
such as red spot, erosion, ulcer and stricture, since CE 
has become available for evaluation of small bowel.20 This 
NSAID-induced enteropathy is often found as an origin of 
obscure GI bleeding in patient taking NSAID. Recently, 
aspirin is also suggested to cause enteropathy similar to 
NSAID-induced enteropathy although its association of 
cause and effect remains clarified.21 In our study, three of 
six patients taking aspirin were diagnosed with 
NSAID-induced enteropathy. One patient taking aceclofe-
nac had negative finding in small bowel on CE.
  The swallowing order of two capsules did not cause any 
significant difference in operating time and diagnostic 
yield (The data were not shown in the Result Section). 
However, one capsule could detect active bleeding focus, 
while the other capsule could detect an ulcer without cur-
rent bleeding at the same site. For example, PillCam SB 
was the second capsule in one patient (Fig. 3), and it de-
tected active bleeding in the small intestine; however, 
MiroCam, the first capsule swallowed 1 h 50 min before, 
found an ulceration without current bleeding at the same 
site. 
  In our study, two capsules were ingested separately to 
avoid visual interference, but in seven patients, the two 
capsule endoscopes were intermittently close to each oth-
er in the small bowel to partially interrupt the visual field 
of one or both by physical obstruction, or by light when 
the light-emitting diode (LED) was on, as shown Fig. 1. 
Two capsule endoscopes can interfere with each other vis-
ually if the times of ingestion are not adequately separated. 
Cave et al.12 reported intermittent visualization of the oth-
er capsule endoscope with a 40-minute interval between 
ingestion. To prevent the encounter of two operating cap-
sule endoscopes, the time interval for ingestion should be 
at least 1 hour. 
  The tumbling movement of capsule endoscopes was 
first observed in a comparison study of EndoCapsule and 
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Fig. 5. In patient 21, the PillCam
SB (A, B) and MiroCam (C, D) 
reveales multiple ulcers.
PillCam SB.12 The present study showed that the tum-
bling movements included oblique inclination and rota-
tion, and that the capsule endoscope rapidly changed its 
position in the small intestine. The tumbling movements 
are illustrated in Fig. 1. When the capsule endoscope is 
positioned randomly, it causes a blind area in the small 
bowel mucosa that decreases the diagnostic yield.12
  Our study has two limitations. Number of the enrolled 
patients were small although of a pilot study. A 
head-to-head prospective study between MiroCam and 
PillCam SB has not been previously evaluated, and there-
fore we tried to compare two capsule endoscopes. The re-
sults of our study showed that MiroCam was comparable 
to PillCam SB in diagnostic yield; however larger scale 
trials are necessary to compare two capsule endoscopes. 
The other problem is the failure to blind the reviewer of 
CE images. The reviewers were gastroenterologists and 
employed in the same hospital where our study was per-
formed, but they were prohibited from participation in 
care of the enrolled patients and were not given in-
formation about the patients. However, the complete 
blindness could not be achieved because the reading pro-
grams of two capsule endoscopes were obviously differ-
ent, and the patients’ names were showed on the reading 
programs. In addition, evaluation of image quality was 
not performed in our study (Figs 4 and 5).
  In conclusion, sequential CE with MiroCam and 
PillCam SB showed slight increase in the diagnostic yield, 
but it was not statistically significant. Two capsule endo-
scopes did not cause interference from each other. 
Further trails to test the efficacy of sequential CE using 
two different capsule endoscopes will be necessary. As 
subsidiary findings, MiroCam had longer operating time, 
higher completion rate, and comparable diagnostic yield, 
compared to PillCam SB in the small bowel disease. 
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